Latest News and Press Releases
Want to stay updated on the latest news?
-
June 3, 2020 AIM: AMYT Euronext Growth: AYP AMRYT PHARMA PLC (“Amryt” or the “Company”) AMRYT AND SWIXX SIGN DISTRIBUTION DEAL FOR MYALEPTA ACROSS 17 JURISDICTIONS IN CENTRAL AND EASTERN EUROPE...
-
May 11, 2020 AIM: AMYT Euronext Growth: AYP AMRYT PHARMA PLC (“Amryt” or the “Company”) Q1 2020 RESULTS $44.6M unaudited Q1 revenues representing a 30% increase on unaudited combined revenues of...
-
May 11, 2020 AIM: AMYT Euronext Growth: AYP AMRYT PHARMA PLC (“Amryt” or the “Company”) FY 2019 RESULTS Transformational year of performance and growth for AmrytAegerion integration...
-
7 May 2020 AIM: AMYT Euronext Growth: AYP AMRYT PHARMA PLC (“Amryt” or the “Company”) FILSUVEZ® CONFIRMED AS GLOBAL BRAND NAME FOR AP101 Amryt, a global, commercial-stage biopharmaceutical company...
-
07 May 2020 AIM: AMYT Euronext Growth: AYP AMRYT PHARMA PLC (“Amryt” or the “Company”) Notice of Results Amryt, a global, commercial-stage biopharmaceutical company dedicated to commercializing and...
-
17 October 2018AIM: AMYTESM: AYP Amryt Pharma plc(“Amryt” or the “Company”) Lojuxta to be reimbursed in France Amryt’s lead commercial product now available in all five of the EU’s largest markets ...
-
10 September 2018AIM: AMYT ESM: AYP Amryt Pharma plc(“Amryt” or the “Company”) Amryt receives IND approval from FDA for AP101 enabling the opening of US clinical trial sites Amryt, a...
-
9 July 2018AIM: AMYT Amryt Pharma plc(“Amryt” or the “Company”) NHS England approves funding for Lojuxta Amryt, a biopharmaceutical company focused on rare and orphan diseases, is pleased to...